Skip to content

Alnylam Pharmaceuticals, Inc. (ALNY) stock: revenue, earnings & dividend

Alnylam Pharmaceuticals, Inc. (ALNY, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener ALNY · Nasdaq Pharma & Biotech US-MA

Key figures

Fiscal year
2025
Revenue
3.71 bn $
Revenue growth
65.2 %
Revenue growth 5y (p.a.)
49.8 %
Net income
314 m $
Net margin
8.5 %
Operating margin
13.5 %
Earnings per share (diluted)
2.33 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
4.97 bn $
Equity
789 m $
Equity ratio
15.9 %
Return on equity
39.8 %
Cash
1.66 bn $
Operating cash flow
524 m $
Free cash flow
465 m $
Shares outstanding
133,937,576

History

Revenue by fiscal year

2016 47.2 m $
2017 89.9 m $
2018 74.9 m $
2019 220 m $
2020 493 m $
2021 844 m $
2022 1.04 bn $
2023 1.83 bn $
2024 2.25 bn $
2025 3.71 bn $

Net income by fiscal year

2016 -410.11 m $
2017 -490.87 m $
2018 -761.5 m $
2019 -886.12 m $
2020 -858.28 m $
2021 -852.82 m $
2022 -1.13 bn $
2023 -440.24 m $
2024 -278.16 m $
2025 314 m $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20253.71 bn $314 m $2.33 $–524 m $
20242.25 bn $-278.16 m $-2.18 $–-8.31 m $
20231.83 bn $-440.24 m $-3.52 $–104 m $
20221.04 bn $-1.13 bn $-9.30 $–-541.27 m $
2021844 m $-852.82 m $-7.20 $–-641.69 m $
2020493 m $-858.28 m $-7.46 $–-614.96 m $
2019220 m $-886.12 m $-8.11 $–-278.43 m $
201874.9 m $-761.5 m $––-562.62 m $
201789.9 m $-490.87 m $––-382.79 m $
201647.2 m $-410.11 m $––-307.7 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)